Illustration of a woman checking blood sugar after weight loss in a clinic, highlighting persistent diabetes risk in high-risk groups.
Illustration of a woman checking blood sugar after weight loss in a clinic, highlighting persistent diabetes risk in high-risk groups.
AI 生成的图像

Study suggests long-term weight loss may not prevent type 2 diabetes in a high-risk metabolic subgroup

AI 生成的图像
事实核查

A lifestyle program that helped participants lose and maintain about 8% of their body weight over roughly nine years did not yield the same metabolic benefits for everyone, according to researchers in Germany. People classified in a high-risk category known as “cluster 5” continued to show worsening blood sugar control and declining insulin secretion despite sustained weight loss.

Scientists at the German Center for Diabetes Research (DZD), University Hospital Tübingen and Helmholtz Munich analyzed data from the Tübingen Lifestyle Intervention Program (TULIP), a study that enrolled people at elevated risk of type 2 diabetes. Participants completed a two-year lifestyle program and were then followed for about nine years.

In the analysis, the researchers focused on people who achieved substantial weight loss and maintained it long term—about 8% of body weight—and assessed whether outcomes differed across previously defined type 2 diabetes risk “clusters.”

The team reported that participants assigned to “cluster 5” showed rising blood glucose levels over time along with declining insulin secretion, indicating a persistently high risk of developing type 2 diabetes even after sustained weight loss. In the ScienceDaily report, lead author Professor Norbert Stefan said the researchers were “very surprised” to see these adverse changes after a long follow-up despite the magnitude and durability of weight reduction.

The study, published in the journal Diabetes, suggests insulin resistance is a major contributor to the ongoing risk in cluster 5 and may be linked to severe fatty liver disease. The researchers said fat accumulation in the liver could also impair pancreatic beta-cell function, reducing the body’s ability to secrete insulin and helping drive higher blood sugar.

The findings add to earlier work indicating that fatty liver disease and insulin resistance are central features of this high-risk subgroup. The authors said that if future prospective research confirms the results, diabetes prevention approaches may need to be more personalized for people with biological profiles like cluster 5, potentially requiring more intensive or targeted strategies than standard lifestyle advice alone.

人们在说什么

Discussions on X focus on the study's finding that sustained weight loss does not equally benefit all diabetes risk clusters, particularly cluster 5 due to insulin resistance and fatty liver. Users share detailed summaries and note implications for personalized prevention. Reactions are neutral and informative, with emphasis on scientific details rather than strong opinions.

相关文章

Illustration of laboratory mice demonstrating effects of a sucrose-free diet on glucose tolerance and gut health.
AI 生成的图像

Mice on sucrose-free low-fat diet showed impaired glucose control and gut inflammation, researchers report

由 AI 报道 AI 生成的图像 事实核查

Eliminating sucrose from a low-fat diet worsened glucose tolerance and altered the gut microbiome in mice over 16 weeks, according to results presented on Saturday, June 13, 2026, at ENDO 2026, the Endocrine Society’s annual meeting in Chicago.

A year-long observational study in Japan suggests that people with type 2 diabetes who tend to overeat in response to tempting food cues such as sight and smell may see greater weight loss—and possibly better blood-sugar improvement—after starting GLP-1 receptor agonists, while those with primarily emotional eating patterns show less consistent links to long-term outcomes.

由 AI 报道

New research shows that the loss of functional fat cells, rather than just excess fat, can lead to diabetes and other metabolic disorders. Scientists studied a rare genetic condition to reveal how damaged adipose tissue disrupts metabolism.

Many adults with type 2 diabetes who pause GLP-1 medications such as semaglutide (Ozempic) later resume treatment, according to research scheduled for presentation at ENDO 2026 in Chicago.

由 AI 报道

A new experimental oral medication called elecoglipron improved blood sugar control and promoted weight loss in adults with type 2 diabetes during a phase 2b trial. Results from the SOLSTICE study were presented at the American Diabetes Association's Scientific Sessions and published in The Lancet.

此网站使用 cookie

我们使用 cookie 进行分析以改进我们的网站。阅读我们的 隐私政策 以获取更多信息。
拒绝